ArticleSurgical endoscopy2026
Perioperative morbidity and midterm outcomes following antireflux surgery in overweight and obese populations.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the worldwide prevalence of obesity increases, more patients with obesity are referred for antireflux surgery (ARS). Although bariatric surgery is typically recommended, at times straightforward ARS is offered. We aimed to compare surgical and patient-reported outcomes among overweight and obese patients undergoing minimally invasive ARS.
methodsThis retrospective cohort study included consecutive patients with BMI ≥ 25 kg/m
resultsA total of 338 patients (71.6% female; median age: 65.1 [54.6-73.1] years) were stratified into the BMI groups: overweight (n = 172, 50.9%), class I (n = 125, 36.9%), class II (n = 30, 8.9%), and class III (n = 11, 3.3%). Intraoperative complication rates (3.5, 4.8, 3.3, and 27.3%; p = 0.006) and ICU admission rates (1.7, 4, 3.3, and 18.2%; p < 0.026) were significantly higher, and early postoperative complications were slightly higher (7.6, 8.8, 6.7, and 27.3%; p = 0.153) in the class III obesity group. Follow-up ≥ 12 months was available for 95/172 (55.2%), 64/125 (51.2%), 15/30 (50%), and 3/11 (27.3%) patients per group with similar median durations (24-36 months). Objective hiatal hernia recurrence (> 2 cm) was observed in 1 overweight and 2 class-I patients, but no class-II/III patients. Improved quality-of-life (GERD-HRQL) scores and high patient satisfaction, especially in the 25-40 kg/m
conclusionMinimally invasive ARS provides a favorable safety profile along with gastroesophageal reflux control and improved quality of life for overweight and non-morbidly obese patients. Particularly, straightforward ARS for patients with class II obesity may be considered when limitations on bariatric surgery exist.
Indexed as
Identifiers
42563044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.